PTPRC and neoplasm: In some instances, the positive effects of the SX-682 chow on the anti-tumor immune environment were thus overridden by the addition of palbociclib (i.e., loss of reduction in Ly6GCD11b+ cells, loss of reduction in CD14+Ly6G+ cells, increase in Ly6C+CD11b+ cells, loss of increase in CD69+ CD8+ T cells, and reduction in total CD45+ cells and loss of increase in CD45+ CD3+ T cells compared to SX-682).